Tivic Health to Report Q1 2024 Financial Results and Subsequent Events on May 15th Via Conference Call and Webcast
Tivic Health, trading under the ticker TIVC, will announce its Q1 2024 financial results on May 15th via a pre-recorded conference call and webcast. The call is scheduled for 1:30 PM PT / 4:30 PM ET. The company specializes in developing and commercializing bioelectronic medicine. Stakeholders can join the call using the provided toll-free and international numbers, or view the webcast online.
- Announcement of Q1 2024 financial results scheduled, providing transparency.
- Pre-recorded call and webcast allow stakeholders global access to company updates.
- Specialization in bioelectronic medicine, a growing field, might attract investor interest.
- The company’s decision to use a pre-recorded format may limit real-time interaction and Q&A opportunities for investors.
Teleconference Details:
Toll Free: 877-545-0523
International: 973-528-0016
Participant Access Code: 464810
Webcast Link
https://www.webcaster4.com/Webcast/Page/2865/50489
About Tivic
Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic’s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Tivic’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic’s first commercial product ClearUP is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors. For more information visit http://tivichealth.com @TivicHealth
Forward-Looking Statements
This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, many of which are out of Tivic’s control. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of relevant risks and uncertainties, and other important factors, any of which could cause Tivic’s actual results to differ from those contained in the forward-looking statements, see Tivic’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 25, 2024, under the heading “Risk Factors”; as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513029294/en/
Investor Contact:
Hanover International, Inc.
ir@tivichealth.com
Source: Tivic Health Systems, Inc.
FAQ
When will Tivic Health announce its Q1 2024 financial results?
How can I participate in Tivic Health's Q1 2024 earnings call?
What is Tivic Health's stock symbol?
What time is Tivic Health's Q1 2024 earnings call?
